{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:01:57Z","timestamp":1790722917428,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["2039\/20"],"award-info":[{"award-number":["2039\/20"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1 R01 HL153988-02A1"],"award-info":[{"award-number":["1 R01 HL153988-02A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["KEREM15XX0"],"award-info":[{"award-number":["KEREM15XX0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["KEREM21GO"],"award-info":[{"award-number":["KEREM21GO"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["LUECK18GO"],"award-info":[{"award-number":["LUECK18GO"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003711","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["3\u201317632"],"award-info":[{"award-number":["3\u201317632"]}],"id":[{"id":"10.13039\/501100003711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jcf.2022.12.016","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T16:06:48Z","timestamp":1673971608000},"page":"S39-S44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"S1","title":["Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3497-8459","authenticated-orcid":false,"given":"Normand E.","family":"Allaire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Griesenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5722-0379","authenticated-orcid":false,"given":"Batsheva","family":"Kerem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1820-711X","authenticated-orcid":false,"given":"John D.","family":"Lueck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemie","family":"Stanleigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifat S.","family":"Oren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2022.12.016_bib0001","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1038\/s41598-019-42404-6","article-title":"Novel, rare and common pathogenic variants in the CFTR gene screened by high-throughput sequencing technology and predicted by in silico tools","volume":"9","author":"Pereira","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2022.12.016_bib0002","unstructured":"https:\/\/www.cff.org\/intro-cf\/about-cystic-fibrosis#:\u223c:text=the%20United%20States%3A-,There%20are%20close%20to%2040%2C000%20children%20and%20adults%20living%20with,CF%20are%20diagnosed%20each%20year."},{"issue":"6","key":"10.1016\/j.jcf.2022.12.016_bib0003","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/MCP.0000000000000327","article-title":"Cystic fibrosis gene therapy: a mutation-independent treatment","volume":"22","author":"Griesenbach","year":"2016","journal-title":"Curr Opin Pulm Med"},{"issue":"9","key":"10.1016\/j.jcf.2022.12.016_bib0004","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-2600(15)00245-3","article-title":"Wolstenholme-Hogg P; UK Cystic Fibrosis Gene Therapy Consortium. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Alton","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2022.12.016_bib0005","unstructured":"Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis (RESTORE-CF)- https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03375047."},{"key":"10.1016\/j.jcf.2022.12.016_bib0006","unstructured":"https:\/\/www.globenewswire.com\/news-release\/2019\/07\/31\/1894563\/0\/en\/Translate-Bio-Announces-Interim-Results-from-Phase-1-2-Clinical-Trial-of-MRT5005-in-Patients-with-Cystic-Fibrosis.html."},{"key":"10.1016\/j.jcf.2022.12.016_bib0007","unstructured":"https:\/\/www.fiercebiotech.com\/biotech\/translate-bio-s-mrna-fails-to-improve-lung-function-cystic-fibrosis-patients."},{"key":"10.1016\/j.jcf.2022.12.016_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/1756285618754459","article-title":"Nusinersen for spinal muscular atrophy","volume":"11","author":"Wurster","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.jcf.2022.12.016_bib0009","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des Devel Ther."},{"issue":"17\u201318","key":"10.1016\/j.jcf.2022.12.016_bib0010","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1089\/hum.2020.169","article-title":"Novel lung tropic Adeno-associated virus capsids for therapeutic gene delivery","volume":"31","author":"Carneiro","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jcf.2022.12.016_bib0011","unstructured":"https:\/\/ir.4dmoleculartherapeutics.com\/news-releases\/news-release-details\/4d-molecular-therapeutics-announces-first-patient-dosed-phase-3."},{"issue":"17","key":"10.1016\/j.jcf.2022.12.016_bib0012","doi-asserted-by":"crossref","first-page":"9023","DOI":"10.1128\/JVI.05154-11","article-title":"Enhanced sialic acid-dependent endocytosis explains the increased efficiency of infection of airway epithelia by a novel adeno-associated virus","volume":"85","author":"Dickey","year":"2011","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.jcf.2022.12.016_bib0013","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1164\/rccm.201206-1056OC","article-title":"Assessment of F\/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy","volume":"186","author":"Griesenbach","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"20","key":"10.1016\/j.jcf.2022.12.016_bib0014","doi-asserted-by":"crossref","first-page":"12818","DOI":"10.1128\/JVI.79.20.12818-12827.2005","article-title":"Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer","volume":"79","author":"Sinn","year":"2005","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.jcf.2022.12.016_bib0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/thoraxjnl-2016-208406","article-title":"Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis","volume":"72","author":"Alton","year":"2017","journal-title":"Thorax"},{"issue":"10","key":"10.1016\/j.jcf.2022.12.016_bib0016","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/gt.2017.78","article-title":"Novel GP64 envelope variants for improved delivery to human airway epithelial cells","volume":"24","author":"Sinn","year":"2017","journal-title":"Gene Ther"},{"key":"10.1016\/j.jcf.2022.12.016_bib0017","unstructured":"https:\/\/www.boehringer-ingelheim.com\/press-release\/cystic-fibrosis-genetherapy-development-option-excercise."},{"key":"10.1016\/j.jcf.2022.12.016_bib0018","unstructured":"https:\/\/ir.krystalbio.com\/news-releases\/news-release-details\/krystal-biotech-receives-approval-human-research-ethics."},{"key":"10.1016\/j.jcf.2022.12.016_bib0019","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05095246."},{"key":"10.1016\/j.jcf.2022.12.016_bib0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13578-021-00662-w","article-title":"Potential of helper-dependent Adenoviral vectors in CRISPR-cas9-mediated lung gene therapy","volume":"11","author":"Bandara","year":"2021","journal-title":"Cell Biosci"},{"issue":"6","key":"10.1016\/j.jcf.2022.12.016_bib0021","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1089\/hum.2017.201","article-title":"Transducing airway basal cells with a helper-dependent adenoviral vector for lung gene therapy","volume":"29","author":"Cao","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jcf.2022.12.016_bib0022","unstructured":"https:\/\/media.nature.com\/original\/magazine-assets\/d43747-021-00073-3\/d43747-021-00073-3.pdf."},{"key":"10.1016\/j.jcf.2022.12.016_bib0023","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jcf.2021.06.003","article-title":"Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10\u00a0kb C-to-T splicing mutation","volume":"20","author":"Oren","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.12.016_bib0024","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/hmg\/8.10.1893","article-title":"Nonsense-mediated mRNA decayin health and disease","volume":"8","author":"Frischmeyer","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jcf.2022.12.016_bib0025","first-page":"222","article-title":"Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease","volume":"50","author":"Shoshani","year":"1992","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jcf.2022.12.016_bib0026","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1165\/rcmb.2006-0176OC","article-title":"Restoration of W1282X CFTR activity by enhanced expression","volume":"37","author":"Rowe","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jcf.2022.12.016_bib0027","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1177\/1087057115605834","article-title":"Facilitating Structure-Function Studies of CFTR Modulator Sites with Efficiencies in Mutagenesis and Functional Screening","volume":"20","author":"Molinski","year":"2015","journal-title":"SLAS Discov"},{"key":"10.1016\/j.jcf.2022.12.016_bib0028","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bcp.2016.09.005","article-title":"The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain","volume":"119","author":"Laselva","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jcf.2022.12.016_bib0029","article-title":"Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation","author":"Oren","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"5857","key":"10.1016\/j.jcf.2022.12.016_bib0030","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/296537a0","article-title":"Construction of a functional human suppressor tRNA gene: an approach to gene therapy for beta-thalassaemia","volume":"296","author":"Temple","year":"1982","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jcf.2022.12.016_bib0031","doi-asserted-by":"crossref","first-page":"e1641","DOI":"10.1002\/wrna.1641","article-title":"Therapeutic promise of engineered nonsense suppressor tRNAs","volume":"12","author":"Porter","year":"2021","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"10.1016\/j.jcf.2022.12.016_bib0032","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1146\/annurev-genom-091212-153527","article-title":"Therapeutics based on stop codon readthrough","volume":"15","author":"Keeling","year":"2014","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"1","key":"10.1016\/j.jcf.2022.12.016_bib0033","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41467-019-08329-4","article-title":"Engineered transfer RNAs for suppression of premature termination codons","volume":"10","author":"Lueck","year":"2019","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.jcf.2022.12.016_bib0034","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcf.2022.12.016_bib0035","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1165\/rcmb.2005-0456OC","article-title":"Anti-inflammatory activity of inhaled IL-4 receptor-\u03b1 antisense oligonucleotide in mice","volume":"36","author":"Karras","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jcf.2022.12.016_bib0036","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3109\/08958378.2014.907587","article-title":"Local and systemic tolerability of a 2\u2032O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-\u03b1 delivery by inhalation in mouse and monkey","volume":"26","author":"Fey","year":"2014","journal-title":"Inhal Toxicol"},{"key":"10.1016\/j.jcf.2022.12.016_bib0037","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.pupt.2008.08.001","article-title":"Advantageous toxicity profile of inhaled antisense oligonucleotides following chronic dosing in non-human primates","volume":"21","author":"Guimond","year":"2008","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jcf.2022.12.016_bib0038","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.ymthe.2017.11.002","article-title":"Oligonucleotide Therapies for the Lung: ready to return to the clinic?","volume":"25","author":"Kumar","year":"2017","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.jcf.2022.12.016_bib0039","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jcf.2017.05.003","article-title":"Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice","volume":"16","author":"Crosby","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2022.12.016_bib0040","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41587-022-01252-y","article-title":"tRNA therapeutics burst onto startup scene","volume":"40","author":"Dolgin","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"7905","key":"10.1016\/j.jcf.2022.12.016_bib0041","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41586-022-04533-3","article-title":"AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice","volume":"604","author":"Wang","year":"2022","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.jcf.2022.12.016_bib0042","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41580-019-0126-2","article-title":"Quality and quantity control of gene expression by nonsense-mediated mRNA decay","volume":"20","author":"Kurosaki","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.jcf.2022.12.016_bib0044","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI28523","article-title":"Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin","volume":"117","author":"Linde","year":"2007","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.jcf.2022.12.016_bib0045","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jcf.2018.12.001","article-title":"Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells","volume":"18","author":"Valley","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2022.12.016_bib0046","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/s41467-022-29935-9","article-title":"CFTR mRNAs with nonsense codons are degraded by the SMG6-mediated endonucleolytic decay pathway","volume":"13","author":"Sanderlin","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcf.2022.12.016_bib0047","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.omtn.2022.04.033","article-title":"Efficient suppression of endogenous CFTR nonsense mutations using anticodon-engineered transfer RNAs","volume":"28","author":"Ko","year":"2022","journal-title":"Mol Ther Nucleic Acids"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322014369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322014369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:47:36Z","timestamp":1761601656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199322014369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":46,"alternative-id":["S1569199322014369"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2022.12.016","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2022.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}